Which Finance - Non Life Insurance Stocks Are Deep Value Picks in Week of Jun 14, 2026?

Sector Pulse

The Non-Life Insurance sector presents a bifurcated picture this quarter. STARHEALTH delivered a blowout performance with PAT surging 416% YoY to Rs. 449 crore, fueled by a 23% growth in Gross Written Premium (Rs. 5,047 crore) and a 320 bps improvement in its combined ratio to 98.9%. Conversely, GICRE posted a mixed quarter; while gross premium income grew 10.2% YoY to INR 10,986.55 crore and its combined ratio improved to 105.32%, PAT declined 6.3% YoY to INR 1,518.92 crore due to elevated loss costs.

Catalysts Playing Out Across the Pack

The dominant theme is tam_expansion_changing_consumption. STARHEALTH is capitalizing on surging retail health insurance demand, which grew at 33.6%—triple the industry average. GICRE is also seeing TAM expansion, noting that climate change impacts are making motor ODs a 'significant opportunity'. Additionally, STARHEALTH is benefiting from mandatory_industry_norms via the landmark GST exemption on retail health, which acts as a structural catalyst lowering all-in insurance costs, and a value_added_product_mix_shift with long-term policies now comprising 51% of GWP. GICRE is eyeing market_share_gains as it reclaims its international book over the next 3-5 years following previous rating downgrades.

What Managements Are Guiding

Forward guidance remains qualitative but confident. GICRE reaffirmed its target of a 1% annual improvement in its composite combined ratio, expecting composite growth of 8% to 10% per annum to mirror the broader Indian insurance market. STARHEALTH is targeting a mid-teens ROE business, leveraging annual price cycles—including a 10% hike for senior citizen products—and expects retail loss ratios to improve further from the current 68.4% as past price hikes flow into earned premiums.

Shared Risks (9-type taxonomy)

regulatory risks are emerging across the board. GICRE faces a potential reduction in obligatory cession rates from the current 4%, though management expects to convert 25% to 50% of this into voluntary business. STARHEALTH is bracing for potential regulatory reviews of expenses of management and commission structures. climate risk is highly active for GICRE, driving elevated loss costs and necessitating a 'strategic CAT reserve' build-up to INR 5,000 crore. Meanwhile, STARHEALTH faces severe commodity risk in the form of medical inflation, which is expected to remain elevated at 12% to 13% in 2026, forcing continuous price hikes. GICRE also noted minor geopolitical risks impacting its motor and cargo books in Israel and Turkey.

Bottom Line

The sector is navigating a complex environment of double-digit top-line growth offset by structural inflation and climate risks. STARHEALTH is currently outperforming by successfully passing on medical inflation through pricing and improving its loss ratios. GICRE is making steady progress on its combined ratio but remains vulnerable to global CAT events and international portfolio volatility. Overall, the sector leans bullish on growth but requires careful monitoring of regulatory shifts and inflation.